Drug candidates often fail in late-stage clinical development due to insufficient efficacy or unfavorable safety profiles. Denovo’s technology offers a transformative solution: by applying our proprietary biomarker discovery platform to archived patient samples, we can retrospectively identify genetic markers that predict treatment response. This enables drug developers to redesign future trials for smaller, genetically enriched patient populations, reducing cost, increasing probability of success, and supporting a personalized medicine strategy.

A key innovation of our platform is its ability to use archived clinical samples to uncover novel genomic biomarkers through whole genome scanning and advanced proprietary analytics developed in-house. This capability—previously not achievable with conventional technologies—creates new opportunities to rescue discontinued assets and accelerate precision neuropsychiatric and neurological drug development.